Comparison of cefuroxime axetil, cefaclor, and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children. 1990

M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
Department of Pediatrics, University of Rochester, NY 14642.

In this randomized, blinded, multicenter comparison study, 377 infants and children with acute otitis media (AOM) received a 10-day course of an oral suspension of one of the following: cefuroxime axetil (CAE), 30 mg/kg/day; cefaclor (CEC), 40 mg/kg/day; or amoxicillin-clavulanate potassium (AMX-CL), 40 mg/kg/day. Clinical efficacy was determined by pneumatic otoscopy and tympanometric testing 3 to 5, 11 to 14, and 22 to 26 days after the initiation of therapy. There was a statistically significant difference among the three treatment groups with respect to clinical outcome; more patients in the CAE group (62%) than in the CEC group (46%) or the AMX-CL group (52%) had complete resolution of signs and symptoms of AOM (including effusion). Paired comparisons revealed a significant difference in efficacy between CAE and CEC and a nearly significant difference between AMX-CL and CEC. Taste acceptability was highest for CEC and lowest for this formulation of CAE. Significantly more patients in the AMX-CL group than in the CAE or CEC group had a side effect, primarily diarrhea, vomiting, or diaper rash. We conclude that CAE suspension has greater clinical efficacy than CEC and fewer side effects than AMX-CL.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010033 Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE. Middle Ear Inflammation,Inflammation, Middle Ear
D002433 Cefaclor Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-,Ceclor,Cefaclor Anhydrous,Cefaclor Monohydrate,Keclor,Lilly 99638,S-6472,S 6472,S6472
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
February 1994, Antimicrobial agents and chemotherapy,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
March 1987, The Pediatric infectious disease journal,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
August 1998, Journal of chemotherapy (Florence, Italy),
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
October 1999, The Pediatric infectious disease journal,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
January 1995, Clinical therapeutics,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
July 1999, Clinical therapeutics,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
November 1998, The Journal of infectious diseases,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
August 1992, Journal of chemotherapy (Florence, Italy),
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
May 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
M Pichichero, and G H Aronovitz, and W M Gooch, and S E McLinn, and B Maddern, and C Johnson, and P M Darden
January 1981, The Annals of otology, rhinology & laryngology. Supplement,
Copied contents to your clipboard!